 |
|
| Systematic (IUPAC) name | |
|---|---|
| N-(4-chlorophenethyl)-3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine | |
| Identifiers | |
| CAS number | 23047-25-8 |
| ATC code | N06AA07 |
| PubChem | 3947 |
| Chemical data | |
| Formula | C26H27ClN2O |
| Mol. mass | 418.958 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Lofepramine (trademarked Gamanil, Tymelyt, generic Lomont) is a third generation tricyclic antidepressant used in the treatment of depressive disorders. It has both antidepressant and anxiolytic properties. Lofepramine is metabolized in vivo into desipramine; hence its pharmacological profile is extremely similar.
Contents |
Indications
In the United Kingdom, lofepramine is licensed for the treatment of depression. Description: An antidepressant administered orally (as tablets). It has fewer sedative properties than many of the products used to treat depressive illnesses and is suited to patients whose symptoms tend towards withdrawal and apathy, rather than restlessness and agitation.
It is commonly prescribed for major depressive disorder, anxiety, insomnia, neuropathic/chronic pain, and treatment resistant depression.[1]
Side effects
Delusions, headache, nightmares, facial oedema, general feeling of being unwell, bleeding from skin, excitement/anxiety, nausea, inflamation of mucous membranes, loss of taste, parasthesia, skin rash, psychiatric problems such as self harm, drowsiness, dry mouth, pins and needles, heartbeat irregularities, sweating, low blood pressure, constipation, blurred vision palpatations, dizziness and urinary retention. Can cause confusion in elderly patients or behavioural disturbance in the young. May produce weight gain or cause changes in the levels of blood sugar. Some patients report muscular discomfort, particularly in the shoulders. However, lofepramine is less sedating than, for instance, amitriptyline, and is safer in overdose than older tricyclics.
Warnings
To be used with caution for epileptic patients or those with glaucoma or psychosis. Lofepramine should not be given to people who have suffered liver failure or heart disease. Not advisable for use in pregnant women.
Availability
In the United Kingdom, lofepramine is marketed (as the hydrochloride salt) in the form of 70 mg tablets and 5ml oral suspension as the generic Lomont.[2]
Development history
G.B. patent 1,177,525 filed on 1967-04-13 by the Swedish Leo corporation (Leo Aktiebolaget) covers Lofepramine as a member of a family of heterocyclic aminoketones, touting as a primary object low toxicity of oral dosage in mice relative to imipramine, amitriptyline, and desipramine for comparable effectiveness.[3]
U.S. patent 3,637,660 granted on 1972-01-25 covers Lofepramine as a member of a family of dibenzazepine derivatives, with similar description and claims.[4]
References
- ^ Essential Psychopharmacology: The Prescriber's Guide, ISBN 0521683505, http://books.google.com/books?id=-ppHkXw5zwMC, p.263
- ^ Lomont , SPC from the eMC
- ^ esp@cenet document view
- ^ Patents: PN/3637660
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
